Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.54 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.48 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 3/20 | 0.41 |
| ▸ | HTR7 | P34969 | 3/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18014704 | 0.84 | CYP2C19 (0.44) | DPP4RIPK1SLC6A2HTR7ALDH1A1 | |
| SCHEMBL22548896 | 0.84 | KCNA5 (0.46) | DPP4RIPK1PDCD1CD274CYP11B1 | |
| SCHEMBL13872997 | 0.84 | PTGS2 (0.43) | DPP4RIPK1HTR7KCNA5KCNH2 | |
| SCHEMBL11060021 | 0.83 | DPP4 (0.55) | DPP4PDCD1CD274KMT2ASLC6A2 | |
| SCHEMBL18014699 | 0.81 | KIF11 (0.47) | RIPK1SLC6A2TACR1HTR7ALDH1A1 | |
| SCHEMBL22548828 | 0.80 | KCNA5 (0.55) | CYP11B1CYP11B2KCNA5KCNH2ALDH1A1 | |
| SCHEMBL12775791 | 0.79 | ATM (0.41) | DPP4RIPK1CYP11B1CYP11B2KCNA5 | |
| SCHEMBL23057561 | 0.79 | DPP4 (0.41) | DPP4RIPK1KMT2ASLC6A2CYP11B1 | |
| SCHEMBL6685097 | 0.78 | RIPK1 (0.56) | RIPK1SLC6A2 | |
| SCHEMBL7450703 | 0.77 | KMT2A (0.50) | DPP4PDCD1CD274KMT2AFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102361837-B | Process for producing conjugated aromatic compound | SUMITOMO CHEMICAL CO | 2014-07-02 | — | — | CN | disclosed |
| CN-102361837-A | Process for producing conjugated aromatic compound | SUMITOMO CHEMICAL CO | 2012-02-22 | — | — | CN | disclosed |
| US-7223774-B2 | Administering enzyme inhibitors of beta secretase, an enzyme responsible for the production of amyloid beta peptide by mediating the cleavage of amyloid precursor proteins; Alzheimer's disease; cognition activators; Down's syndrome; neurodegenerative diseases; other dementias of mixed origins | ELAN PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20050032848-A1 | Administering enzyme inhibitors of beta secretase, an enzyme responsible for the production of amyloid beta peptide by mediating the cleavage of amyloid precursor proteins; Alzheimer's disease; cognition activators; Down's syndrome; neurodegenerative diseases; other dementias of mixed origins | ELAN PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032848-A1 | Administering enzyme inhibitors of beta secretase, an enzyme responsible for the production of amyloid beta peptide by mediating the cleavage of amyloid precursor proteins; Alzheimer's disease; cognition activators; Down's syndrome; neurodegenerative diseases; other dementias of mixed origins | BACE1, BACE2, APP | DPP4 333/4885RIPK1 2458/4885PDCD1 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.